Zusammensetzungen zur Behandlung von Cftr-Vermittelten Erkrankungen

Details

Veröffentlichungs-Nr.

EP4755448

Anmeldetag

6. Februar 2025

Veröffentlichung

10. Juni 2026

Rechtsraum

EP

IPC

A61P11/00

Abstract

The present invention relates to pharmaceutical compositions formulated into a plurality of granules containing calcium bis((14S)-8-[3-(2-{dispiro[2.0.2<4>.1<3>]heptan-7-yl}ethoxy)pyrazol-1-yl]-12,12-dimethyl-2,2,4-trioxo-2λ<6>-thia-3,9,11,18,23-pentaazatetracyclo[17.3.1.1<11>,<14>.0<5>,<10>]tetracosa-1(23),5,7,9,19,21-hexaen-3-ide), a solid dispersion of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, and a solid dispersion of N-(2-(tert-butyl)-5-hydroxy-4-(2-(methyl-d<3>)propan-2-yl-1,1,1,3,3,3-d<6>)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide, methods for manufacturing and processing the granules, and methods for treating cystic fibrosis employing the pharmaceutical compositions.

Anmelder

Firma

Vertex Pharmaceuticals Incorporated

Land

🇺🇸 USA

Fachgebiete